Search
TA-CIN
go.drugbank.com/drugs/DB05809InvestigationalTA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.
Synonyms: TA-CINAdafosbuvir
go.drugbank.com/drugs/DB14906InvestigationalAdafosbuvir is under investigation in clinical trial NCT02894905 (A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335).
AICA ribonucleotide
go.drugbank.com/drugs/DB01700InvestigationalThe drug was first used in the 1980s as a method to preserve blood flow to the heart during surgery and is currently of interest as a potential treatment for diabetes by increasing the metabolic activity … of tissues by changing the physical composition of muscle.
CE-224535
go.drugbank.com/drugs/DB12113InvestigationalCE-224535 has been used in trials studying the treatment of Osteoarthritis.
Categories: Purinergic P2X Receptor AgonistsPentetreotide
go.drugbank.com/drugs/DB12602ApprovedWithdrawnPentetreotide has been used in trials studying the diagnosis of Cushing's syndrome.
CE-326597
go.drugbank.com/drugs/DB12694InvestigationalCE-326,597 has been used in trials studying the treatment of Obesity.
Gaxilose
go.drugbank.com/drugs/DB12767ApprovedWithdrawnGaxilose has been used in trials studying the diagnostic of Lactose Intolerance.
Parethoxycaine
go.drugbank.com/drugs/DB19380ApprovedWithdrawnParethoxycaine is a local anesthetic that was previously approved in the US.
ARCoV
go.drugbank.com/drugs/DB15855ExperimentalSARS-CoV-2 mRNA vaccine (ARCoV) is a novel mRNA coronavirus vaccine that consists of a lipid nanoparticle-encapsulated mRNA encoding the receptor binding domain of SARS-CoV-2[A220048]. … It is the first COVID-19 mRNA vaccine to be approved for clinical trials in China, and was co-developed by Abogen Biosciences, Walvax Biotechnolgoy Co., Ltd. and the People’s Liberation Army (PLA) Academy
Maxy-G34
go.drugbank.com/drugs/DB05718Investigational, while Neulasta has a single 20 Kd PEG group attached at the N terminal end of the wild type G-CSF protein. … wild type human G-CSF to avoid PEGylation of such sites.